Rawstron A - Search Results

1

FcRL5 as a target of antibody-drug conjugates for the treatment of multiple myeloma.

Elkins K, Zheng B, Go M, Slaga D, Du C, Scales SJ, Yu SF, McBride J, de Tute R, Rawstron A, Jack AS, Ebens A, Polson AG. Elkins K, et al. Among authors: rawstron a. Mol Cancer Ther. 2012 Oct;11(10):2222-32. doi: 10.1158/1535-7163.MCT-12-0087. Epub 2012 Jul 17. Mol Cancer Ther. 2012. PMID: 22807577

2

Assessment of IgH PCR strategies in multiple myeloma.

Owen RG, Johnson RJ, Rawstron AC, Evans PA, Jack A, Smith GM, Child JA, Morgan GJ. Owen RG, et al. Among authors: rawstron ac. J Clin Pathol. 1996 Aug;49(8):672-5. doi: 10.1136/jcp.49.8.672. J Clin Pathol. 1996. PMID: 8881921 Free PMC article.

3

Circulating plasma cells in multiple myeloma: characterization and correlation with disease stage.

Rawstron AC, Owen RG, Davies FE, Johnson RJ, Jones RA, Richards SJ, Evans PA, Child JA, Smith GM, Jack AS, Morgan GJ. Rawstron AC, et al. Br J Haematol. 1997 Apr;97(1):46-55. doi: 10.1046/j.1365-2141.1997.72653.x. Br J Haematol. 1997. PMID: 9136941 Free article.

4

p53 gene mutations in multiple myeloma.

Owen RG, Davis SA, Randerson J, Rawstron AC, Davies F, Child JA, Jack AS, Morgan GJ. Owen RG, et al. Among authors: rawstron ac. Mol Pathol. 1997 Feb;50(1):18-20. doi: 10.1136/mp.50.1.18. Mol Pathol. 1997. PMID: 9208809 Free PMC article.

5

B-lymphocyte suppression in multiple myeloma is a reversible phenomenon specific to normal B-cell progenitors and plasma cell precursors.

Rawstron AC, Davies FE, Owen RG, English A, Pratt G, Child JA, Jack AS, Morgan GJ. Rawstron AC, et al. Br J Haematol. 1998 Jan;100(1):176-83. doi: 10.1046/j.1365-2141.1998.00525.x. Br J Haematol. 1998. PMID: 9450807 Free article.

6

Interleukin 6, tumour necrosis factor alpha and lymphotoxin alpha polymorphisms in monoclonal gammopathy of uncertain significance and multiple myeloma.

Dring AM, Davies FE, Rollinson SJ, Roddam PL, Rawstron AC, Child JA, Jack AS, Morgan GJ. Dring AM, et al. Among authors: rawstron ac. Br J Haematol. 2001 Jan;112(1):249-51. doi: 10.1046/j.1365-2141.2001.02497-2a.x. Br J Haematol. 2001. PMID: 11167813 Free article. No abstract available.

7

In multiple myeloma, only a single stage of neoplastic plasma cell differentiation can be identified by VLA-5 and CD45 expression.

Rawstron AC, Barrans SL, Blythe D, English A, Richards SJ, Fenton JA, Davies FE, Child JA, Jack AS, Morgan GJ. Rawstron AC, et al. Br J Haematol. 2001 Jun;113(3):794-802. doi: 10.1046/j.1365-2141.2001.02730.x. Br J Haematol. 2001. PMID: 11380472 Free article.

8

Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation.

Rawstron AC, Davies FE, DasGupta R, Ashcroft AJ, Patmore R, Drayson MT, Owen RG, Jack AS, Child JA, Morgan GJ. Rawstron AC, et al. Blood. 2002 Nov 1;100(9):3095-100. doi: 10.1182/blood-2001-12-0297. Blood. 2002. PMID: 12384404 Free article.

9

Demonstration of a germinal center immunophenotype in lymphomas by immunocytochemistry and flow cytometry.

Jack A, Barrans S, Blythe D, Rawstron A. Jack A, et al. Among authors: rawstron a. Methods Mol Med. 2005;115:65-91. doi: 10.1385/1-59259-936-2:065. Methods Mol Med. 2005. PMID: 15998963

10

Flow cytometric protein expression profiling as a systematic approach for developing disease-specific assays: identification of a chronic lymphocytic leukaemia-specific assay for use in rituximab-containing regimens.

Rawstron AC, de Tute R, Jack AS, Hillmen P. Rawstron AC, et al. Leukemia. 2006 Dec;20(12):2102-10. doi: 10.1038/sj.leu.2404416. Epub 2006 Oct 19. Leukemia. 2006. PMID: 17051247

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

174 results

Search Page

Filters